3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Polycythemia Vera
3
Thrombocythemia, Essential
2
Philadelphia Chromosome
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Brain Neoplasms
2
Skin Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Leukemia
1
Glioma
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
Cyclophosphamide
37
fludarabine phosphate
33
Peripheral Blood Stem Cell Transplantation
29
Methotrexate
27
Busulfan
26
Tacrolimus
24
Cytarabine
21
Antilymphocyte Serum
20
Cyclosporine
19
Mycophenolic Acid
18
Whole-Body Irradiation
17
Radiotherapy
15
Methylprednisolone
15
Filgrastim
13
merphos
10
Melphalan
10
Cord Blood Stem Cell Transplantation
10
Imatinib Mesylate
9
Etoposide
9
Granulocyte Colony-Stimulating Factor
7
Thiotepa
6
Rituximab
6
sargramostim
5
fludarabine
5
Vincristine
5
Sirolimus
5
Prednisone
5
Idarubicin
5
Cladribine
5
thymoglobulin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Blast Crisis
×
peginterferon alfa-2a
×
Clear all
NCT00763763
2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
55 enrolled